Artificial intelligence is revolutionizing medical science through advanced diagnostics and AI-powered tools. Now comes AI for breakthrough drug discovery and development.
Danish drug manufacturer Novo Nordisk has announced plans to collaborate with OpenAI, with the aim of using artificial intelligence to increase the efficiency of drug discovery.
Under this partnership, the drugmaker and competitor to Eli Lilly will deploy AI tools across its business, ranging from drug discovery to manufacturing to commercial operations.
Additionally, the makers of Wegovy and Ozempic will use OpenAI’s technology to assess complex data sets and identify promising drug candidates.
These tools will also increase efficiency and remove obstacles in supply chains, drug distribution and procurement activities.
Novo said the partnership also included strict data protection, governance and human oversight, involving other technology partners and research organizations.
On OpenAI’s part, the tech company will train Novo’s global strength by equipping them with AI literacy and required skills.
Further details, such as the financial terms of the agreement, have not yet been disclosed. Speaking of the timeline, the company is expected to begin full integration pilot programs in late 2026.
Is AI intended to replace scientists?
Given the increasing integration of AI, it is generally feared that AI will soon also replace scientists, making them irrelevant in the field of drug discovery.
According to CEO Mike Doustda, “The goal here is not to replace our scientists. It’s about boosting them.”
The head of OpenAI also issued a statement: “AI is reshaping industries and in life sciences it can help people live better, longer lives.”
“This collaboration with Novo Nordisk will help them accelerate scientific discovery, conduct smarter global operations and redefine the future of patient care.” he added.
AI revolution in drug discovery
In the rapidly evolving era of artificial intelligence, AI performs many tasks performed by drug manufacturers.
To streamline the more tedious aspects of drug development, pharmaceutical companies are increasingly relying on AI. They use it for everything from identifying clinical trial participants and selecting trial sites to preparing complex regulatory dossiers.
Using generative AI, researchers at the Massachusetts Institute of Technology have designed new antibiotics to combat two drug-resistant infections gonorrhea (Neisseria gonorrhoeae) and methicillin-resistant (Staphylococcus aureus) MRSA.
AI can also perform ‘freestyle’ molecular design or build on existing molecules, narrowing the millions of possibilities into hours instead of years
AI is also used to reuse existing medicines. That’s why these models are used to ‘map’ the world’s 8,000 approved drugs against 17,000 diseases.
Despite these breakthroughs, AI models have not yet fully mastered the ‘holy grail’ of drug development.
